C4 Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About C4 Therapeutics, Inc.

C4 Therapeutics, Inc. (NASDAQ: CCCC) is a US-listed biopharmaceutical company headquartered in Watertown, Massachusetts, United States, and founded in 2015. For investors, it fits the profile of a clinical-stage biotech focused on a differentiated scientific platform rather than a commercialized product portfolio. The company’s core mission is to harness targeted protein degradation (TPD), an approach intended to eliminate disease-causing proteins instead of merely inhibiting them. ([c4therapeutics.com](https://c4therapeutics.com/our-company/?utm_source=openai)) C4 Therapeutics’ proprietary TORPEDO® platform is designed to discover and optimize small-molecule degraders efficiently, leveraging the body’s natural protein recycling machinery. Management presents the platform as a potential way to address hard-to-drug targets, overcome resistance mechanisms and create oral medicines with high potency and specificity. In competitive terms, C4T operates in the emerging protein-degradation space, where scientific credibility, translational execution and partnership quality matter as much as headline clinical assets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1662579/000156459022006499/cccc-10k_20211231.htm?utm_source=openai)) The company’s most important internal programs are concentrated in oncology. Cemsidomide is an IKZF1/3 degrader being advanced for relapsed/refractory multiple myeloma, including later-stage development activity in 2026. CFT1946 targets BRAF V600 mutations in solid tumors, while CFT8919 is an EGFR L858R degrader being developed for non-small-cell lung cancer, with initial work conducted in Greater China through a partner. Beyond these lead programs, C4 Therapeutics continues to explore additional discovery efforts in inflammation, neuroinflammation and neurodegeneration, which broadens the platform narrative beyond oncology over time. ([ir.c4therapeutics.com](https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-reports-fourth-quarter-and-full-year-2025?utm_source=openai)) Geographically, the company remains anchored in the United States, with research and corporate operations in Watertown, Massachusetts, while leveraging a network of global collaborations. Strategic partnerships with Roche, Biogen, Merck KGaA and Pfizer show that C4T uses collaboration both to validate its science and to help finance development. That model can reduce some standalone development burden, but it also means future value creation depends heavily on partner execution and milestone delivery. ([ir.c4therapeutics.com](https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-announces-transformation-strategic-collaboration/?utm_source=openai)) Recent developments reinforce the investment case as a catalyst-driven biotech story. In 2025–2026, C4 Therapeutics reported that cemsidomide advanced into Phase 2 MOMENTUM in fourth-line-or-later multiple myeloma, with a combination study with elranatamab expected to begin in Q2 2026. The company also highlighted that a second degrader designed and delivered to Biogen entered clinical development for autoimmune disease, and its year-end 2025 update disclosed cash, cash equivalents and marketable securities of $297.1 million, supporting runway into the end of 2028. ([ir.c4therapeutics.com](https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-reports-fourth-quarter-and-full-year-2025?utm_source=openai))